Skip to main content

LSBC Appoints Sainsbury Laboratory Scientist to Scientific Advisory Board; Funds His Research

NEW YORK, June 26 - Large Scale Biology has hired David Baulcombe, a professor at The Sainsbury Laboratory in Norwich, UK, as a consultant and appointed him to the company's scientific advisory board, LSBC said Tuesday.  

"Professor Baulcombe is recognized as a world leader in characterizing the mechanisms of post-transcriptional gene silencing, currently known as RNA interference, and has helped demonstrate the utility of this phenomenon to determine gene function in higher organisms," said Laurence Grill, senior vice president of R&D and co-founder of LSBC, in a statement.

The company will also fund a research program in Baulcombe's laboratory for a period of three years to study next-generation viral-derived gene silencing and overexpression technologies, LSBC said in a statement.

The development comes less than a week after LSBC announced an agreement to license similar viral-derived gene silencing and overexpression technology--which Baulcombe and his colleagues developed--from Plant Bioscience, an intellectual property management company based in Norwich. LSBC plans to use the technology in conjunction with its Geneware plant viral vectors.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.